NCT01974232CompletedNot Applicable
A Retrospective Chart Review of Thirty Three Children Who Have Received Clinical Treatment With Either Romiplostim or Eltrombopag From 2009-2013
Weill Medical College of Cornell University1 site in 1 country33 target enrollmentStarted: January 2012Last updated:
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Enrollment
- 33
- Locations
- 1
- Primary Endpoint
- Platelet count greater than or = to 50,000
Study Overview
Brief Summary
This is a retrospective analysis of children (≤21years old) who received clinical treatment with either Romiplostim or Eltrombopag at 2 medical centers from 2009-2013. The children included in this study were from Weill Medical College of Cornell University, New York, New York and Children's Hospital Orange County, Orange, California
Study Design
- Study Type
- Observational
- Observational Model
- Case Only
- Time Perspective
- Retrospective
Eligibility Criteria
- Ages
- 19 Months to 21 Years (Child, Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •All patients in this study had received prior treatments before the start of TPO treatment including corticosteroids, IVIG, IV anti-D, and/or Rituximab.
Exclusion Criteria
- •Children who do not have ITP
Outcomes
Primary Outcomes
Platelet count greater than or = to 50,000
Time Frame: on two consecutive weeks
Secondary Outcomes
- An increase in platelets greater than or = to 20,000 over baseline.(On two consecutive weeks)
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Completed
Not Applicable
Pediatric Disease Registry in Essential Thrombocythaemia (ET)Essential Thrombocythemia (ET)NCT01198717Shire60
Completed
Not Applicable
Romiplostim Treatment for Thrombocytopenia in Patients With Wiskott-Aldrich Syndrome.Wiskott-Aldrich SyndromeNCT04350164Federal Research Institute of Pediatric Hematology, Oncology and Immunology67
Active, not recruiting
Phase 1
A Prospective Follow-Up Study of Children Aged 23 to 25 months, Born to Mothers Who Received Hydroxyprogesterone Caproate Injection, 250 mg/mL, or Vehicle for Prevention of Preterm BirthThis is a prospective, follow-up, designed to provide an assessment of the development of children born to mothers enrolled in the trial of the effectiveness of 17PMedDRA version: 14.1Level: LLTClassification code 10036594Term: Premature birthSystem Organ Class: 10036585 - Pregnancy, puerperium and perinatal conditionsEUCTR2011-000105-53-CZKV Pharmaceutical Co.375
Completed
Not Applicable
Retrospective Chart Review Study of Patients With PIK3CA-Related Overgrowth Spectrum Who Have Received AlpelisibPIK3CA-Related Overgrowth Spectrum (PROS)NCT04285723Novartis Pharmaceuticals57
Completed
Phase 3
A Phase III Study of a 2-dose Regimen of a Multivalent Human Papillomavirus (HPV) Vaccine (V503), Administered to 9 to 14 Year-olds and Compared to Young Women, 16 to 26 Years Old (V503-010)Human Papillomavirus InfectionNCT01984697Merck Sharp & Dohme LLC1,518